Investor Communication

Beta Drugs Targets Vision 2030 Revenue Expansion; Expects Strong Export Recovery and Margin Improvement in FY27

NSE

beta

BSE

Not listed

Beta Drugs Limited, during its Q4 FY26 earnings conference call, outlined its Vision 2030 strategy targeting revenue expansion to ₹850-₹900 crore over the next four years. Management highlighted recovery in export tenders, continued growth in branded oncology, scaling of dermatology and IVF businesses, and margin expansion driven by higher branded and export contribution.

PRICE-SENSITIVE TRIGGER

Event: Q4 FY26 Earnings Conference Call and Strategic Business Outlook

Type: Business Update & Investor Communication

Impact: Positive

Immediate Effect: Management reiterated confidence in achieving 20%-25% annual growth, guided for stronger FY27 exports, improved EBITDA margins, and highlighted strategic diversification into IVF and cosmetology alongside oncology leadership.

Key Metrics:

FY26 Net Revenue:
- ₹396 crore
- Up from ₹368 crore YoY
Gross Margin:
- 55.52%
- Vs 52.71% YoY
EBITDA:
- ₹86.85 crore
- Vs ₹76.97 crore YoY
EBITDA Margin:
- 22.57%
- Vs 21.1% YoY
Operating Margin:
- 18.11%
- Vs 17.65% YoY
PAT Margin:
- 10.78%
- Vs 11.71% YoY
- Adjusted PAT margin would have exceeded 12.5% excluding extraordinary CCD-related expenses
Branded Oncology Sales:
- ₹123 crore
- Up 20% YoY
CDMO Sales:
- ₹149 crore
- Up 1% YoY
Export Sales:
- ₹71 crore
- Down 11% YoY due to delayed tenders
Derma Sales:
- ₹16.58 crore
- Up 35% YoY
API Sales:
- ₹25 crore
- Up 23% YoY
Nivian Lifesciences FY26 Revenue:
- ₹45-46 crore
Nivian EBITDA Margin:
- 18%-19%

Highlight:

Beta Drugs expects export sales growth of over 50% in FY27 after delayed international tenders were awarded in March FY26.

What Happened ?

Beta Drugs Limited held its Q4 FY26 earnings conference call and detailed its operational roadmap for FY27 and Vision 2030 expansion strategy.

Management acknowledged that FY26 growth remained below internal expectations due to:

Delayed export tenders
Sharp decline in domestic Platin supplies caused by unfavorable NPPA-linked economics
Temporary export execution disruptions

Despite these challenges, the company reported:

Higher gross margins
Improved EBITDA margins
Strong branded oncology momentum
Positive EBITDA contribution from the dermatology segment
Expansion into IVF therapies through acquisition of Nivian Lifesciences

The company acquired a 66.1% stake in Nivian Lifesciences for ₹69.4 crore at an enterprise valuation of ₹105 crore. Management expects strong operational synergies through procurement efficiencies, corporate hospital access, and product expansion.

Beta also:

Submitted over 200 export dossiers in the last 18 months
Plans EU audits in FY27
Targets exports contributing 30% of total revenue by FY30
Continues expanding NDDS oncology products and specialty therapies

Management reiterated confidence in achieving ₹850-₹900 crore revenue by FY30.

Key Details

Operational and Strategic Highlights:

Export tender delays impacted FY26 revenues by approximately ₹20-25 crore.
Export supplies from delayed tenders will commence from Q1 FY27.
Company expects at least 50% export growth in FY27.
Beta submitted over 200 dossiers globally and expects nearly 100 registrations this year.
EU audit is scheduled for September FY27.
Export business currently operates across around 30 countries and plans expansion to 45 countries.
Top five export geographies are expected to contribute nearly 30% of export revenues.
Branded oncology business is expected to continue growing at 20%-25%.
Company launched:
- 2 NDDS products in FY26
- 5 new products during the year
Around 20-25 additional launches are planned over the next 3-4 years.
Dermatology division turned EBITDA positive in FY26.
Cosmetology division targets:
- ₹50 crore revenue over next three years
- EBITDA margins of 12%-14%
Intermediate/KSM plant commercialization expected during FY27.
Management estimates:
- 1%-1.5% margin improvement from in-house KSM production
- Reduced China dependency
- Better DMF and dossier control
Existing manufacturing infrastructure can support ₹700-₹800 crore revenue without major capex.
Planned capex over next two years:
- Around ₹25 crore
FY30 revenue mix target:
- Branded formulations: 51%
- Exports: 30%
- CDMO share to decline materially

Note:

Management stated that FY26 disruptions were largely external and transitional, while strategic groundwork laid during the year is expected to accelerate growth from FY27 onward.

Risk Analysis

Summary:

While Beta Drugs outlined aggressive medium-term growth plans, execution risks remain linked to export tender timing, regulatory approvals, dependence on international registrations, and scaling of new verticals.

Key Risks:

Export revenues remain partly dependent on government tender cycles across multiple countries.
Delay in international tender awards negatively impacted FY26 revenue visibility.
Oncology Platin portfolio continues facing pricing pressure due to NPPA economics.
EU regulatory audits and dossier approvals remain critical for regulated market expansion.
Integration and scaling of Nivian Lifesciences carries execution and operational risks.
Dermatology and IVF expansion require sustained product acceptance and market penetration.
Dependence on a few key export geographies could create concentration risks.
Margin expansion assumptions depend on successful branded mix improvement and export scaling.

Worst Case Scenario:

If export tender cycles face further delays, regulated market approvals get postponed, or margin recovery from branded and export businesses fails to materialize, Beta Drugs may miss its FY30 revenue and profitability targets.

Risk Level: Medium

Company Commentary

Management reaffirmed its Vision 2030 target of ₹850-₹900 crore revenue over the next four years.
The company expects exports to contribute nearly 30% of total revenue by FY30.
Beta stated that oncology remains its core focus and does not foresee structural slowdown in the segment.
Management highlighted that delayed FY26 exports have already been awarded and execution starts from Q1 FY27.
The company expects branded oncology business to continue growing at 20%-25%.
Beta Drugs stated that dermatology, IVF, exports, and specialty launches will act as future growth drivers.
Management believes Nivian acquisition offers strong synergies through procurement efficiencies, hospital access, and product expansion.
Company indicated that no major capex is required to support medium-term growth due to available manufacturing capacity.

Official Exchange Filing: Beta Drugs Limited